References
- Cronstein BN. Low-dose methotrexate: a mainstay in the treat-ment of rheumatoid arthritis. Pharmacol Rev 2005;57:163–72.
- Perruquet JL, Harrington TM, Davis DE. Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthri-tis. Arthritis Rheum 1983;26:1291–2.
- Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis 2002;8:891–6.
- Roblot F, Godet C, Le Moal G, Garo B, Faouzi Somata M, Dary M, et al. Analysis of underlying diseases and prognosis factors as-sociated with Pneumocystis carinii pneumonia in immuno-compromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523–31.
- Maskell NA, Waine DJ, Lindley A, Pepperall JCT, Wakefield AE, Miller RF, et al. Asymptomatic carriage of Pneumocyctis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003;58:594–7.
- Flori P, Bellete B, Durand F, Raberin H, Cazorla C, Hafid J, et al. Comparison between real-time PCR, conventional PCR and dif-ferent staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004;53:603–7.
- Barrera P, Laan RF, van RPL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994;53:434–9.
- Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occur-rence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Ftheumatol 1996;35:441–5.
- Clerc D, Brousse C, Mariette X, Bennet P, Bisson M. Cytomega-lovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone. Ann Rheum Dis 1991;50:67.
- Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Ftheumatol 1991;18:1172–5.
- LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150:258–60.
- Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action on methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2004;114:154–63.
- Stenger AA, Houtman PM, Bruyn GA, Eggink HF, Pasma HR. Pneumocystis carinii pneumonia associated with low dose metho-trexate treatment for rheumatoid arthritis. Scand J Ftheumatol 1994;23:51–3.
- Takeda Y, Tsuji T, Misumi M, Ideguchi H, Ueda A, Ohno S, et al. Pneumocystis carinii pneumonia associated with low dose metho-trexate treatment for malignant rheumatoid arthritis. Ftinsho Ftiumachi 2001;13:293–9.
- Hashimoto H. Prophylaxis of Pneumocystis jiroveci pneumonia in autoimmune disease (in Japanese). In: Hashimoto H, editor. Clini-cal guideline. Tokyo: Japanese Ministry of Health, Labour and Welfare Study Group on complication and treatment of immune disease; 2005. p. 14–9.
- Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infu-sion of infliximab. Rheumatology 2002;41:951–2.
- Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E, Koren G. Interaction between trimethoprim-sulfamethoxazole and methotr-exate in children with leukemia. J Pediatr 1990;117:823–6.
- Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole - a potentially hazardous combination. Clin Exp Dermatol 1990;15:358–60.